Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and
rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or
marrow stem cells is safe. Another goal is to learn if this treatment can help decrease the
chances of the cancer coming back.